Clinical Neuropathology QUIZ #20

JavaScript isn't enabled in your browser, so this file can't be opened. Enable and reload.

Published in Clinical Neuropathology Vol 42 nr.4 (July-August 2023). Based on papers and editorial of Clinical Neuropathology of the same issue: https://www.dustri.com/nc/journals-in-english/mag/clinical-neuropathology/vol/volume-42-2023/issue/julyaugust-16.html

1. Which of the following gliomas shows a FLAIR mismatch sign on MRI imaging?

1 point

a - Glioblastoma, IDH-wildtype

b - Supratentorial ependymoma

c - Astrocytoma, IDH-mutant

d - Oligodendroglioma, IDH-mutant and 1p/19q codeleted

e - Ganglioglioma

2. Which of the following imaging features is more frequent in MGMT promoter-methylated glioblastomas than in MGMT wildtype glioblastomas?

1 point

a - Low apparent diffusion coefficient (ADC)

b - Low perfusion

c - More edema

d - Calcification

e - Cysts

3. Which of the following histological features can be observed in metastases of non-small cell lung carcinoma (NSCLC) as compared to the primary tumors?

1 point

a - Fewer CD4+ cells

b - Fewer CD8+ cells

c - Higher levels of pannexin (PANX1) expression

d - Fewer CD68+ cells

e - All of the above

4. Which of the following markers is typically positive in the neoplastic cells of classic Hodgkin lymphoma? *

1 point

a - CD15

b - CD30

c - EBV-encoded small nuclear RNAs (EBER) (in situ hybridization)

d - EBV-latent membrane protein 1 (LMP1)

e - All of the above

5. Which of the following tumors features the highest expression of Ras signaling pathway proteins?

1 point

a - Malignant peripheral nerve sheath tumors (MPNSTs)

b - Cutaneous neurofibromas

c - Diffuse neurofibromas

d - Plexiform neurofibroma

e - Diffuse plexiform neurofibroma

Submit

Clear form

This form was created inside of Euro-CNS. Report Abuse

Forms